TY - JOUR
T1 - Consensus for HER2 alterations testing in non-small-cell lung cancer
AU - Ren, S.
AU - Wang, J.
AU - Ying, J.
AU - Mitsudomi, T.
AU - Lee, D. H.
AU - Wang, Z.
AU - Chu, Q.
AU - Mack, P. C.
AU - Cheng, Y.
AU - Duan, J.
AU - Fan, Y.
AU - Han, B.
AU - Hui, Z.
AU - Liu, A.
AU - Liu, J.
AU - Lu, Y.
AU - Ma, Z.
AU - Shi, M.
AU - Shu, Y.
AU - Song, Q.
AU - Song, X.
AU - Song, Y.
AU - Wang, C.
AU - Wang, X.
AU - Xu, Y.
AU - Yao, Y.
AU - Zhang, L.
AU - Zhao, M.
AU - Zhu, B.
AU - Zhang, J.
AU - Zhou, C.
AU - Hirsch, F. R.
N1 - Funding Information:
This study was also supported in part by the Backbone Program of Shanghai Pulmonary Hospital (No. FKGG1802), Shanghai Pujiang Talent Plan (No. 2019PJD048), Shanghai Science and Technology Committee Foundation (NO. 19411950300), Shanghai Key disciplines of Respiratory (No. 2017ZZ02012), Shanghai Multidisciplinary Cooperative Project for Diagnosis and Treatment of Major Diseases, and Key Clinical Project Development Program of Shanghai. JZ served as a scientific advisor/consultant for AstraZeneca, Biodesix, Novocure, Bayer, Daiichi Sankyo, Mirati, Novartis, Cardinal Health, Bristol Myers Squibb, Nexus Health and Sanofi, is on the speakers? bureau for AstraZeneca and MJH Life Sciences and has received research funding from AstraZeneca, Biodesix, Novartis, Genentech/Roche, Mirati, AbbVie and Hengrui Therapeutics. FRH participated in scientific advisory boards for: Bristol Myers Squibb, Genentech, Merck, Novartis, AstraZeneca/Daiichi, Sanofi/Regeneron, OncoCyte. CZ reported honoraria as a speaker from Roche, Lily China, Boehringer Ingelheim, Merck, Hengrui, Qilu, Sanofi, Merck Sharp & Dohme, Innovent Biologics, C-Stone, Luye Pharma, TopAlliance Biosciences, and Amoy Diagnositics; and advisor fees for Innovent Biologics, Hengrui, Qilu, and TopAlliance Biosciences. SR reported honoraria as a speaker from Boehringer Ingelheim, Lilly, Merck Sharp & Dohme, Roche, Hengrui, and Junshi, advisor fees for Roche, Merck Sharp & Dohme, and Boehringer Ingelheim and research funding from Hengrui. All other authors have declared no conflicts of interest.
Funding Information:
JZ served as a scientific advisor/consultant for AstraZeneca, Biodesix, Novocure, Bayer, Daiichi Sankyo, Mirati, Novartis, Cardinal Health, Bristol Myers Squibb, Nexus Health and Sanofi, is on the speakers’ bureau for AstraZeneca and MJH Life Sciences and has received research funding from AstraZeneca, Biodesix, Novartis, Genentech/Roche, Mirati, AbbVie and Hengrui Therapeutics. FRH participated in scientific advisory boards for: Bristol Myers Squibb, Genentech, Merck, Novartis, AstraZeneca/Daiichi, Sanofi/Regeneron, OncoCyte. CZ reported honoraria as a speaker from Roche, Lily China, Boehringer Ingelheim, Merck, Hengrui, Qilu, Sanofi, Merck Sharp & Dohme, Innovent Biologics, C-Stone, Luye Pharma, TopAlliance Biosciences, and Amoy Diagnositics; and advisor fees for Innovent Biologics, Hengrui, Qilu, and TopAlliance Biosciences. SR reported honoraria as a speaker from Boehringer Ingelheim, Lilly, Merck Sharp & Dohme, Roche, Hengrui, and Junshi, advisor fees for Roche, Merck Sharp & Dohme, and Boehringer Ingelheim and research funding from Hengrui. All other authors have declared no conflicts of interest.
Funding Information:
This study was also supported in part by the Backbone Program of Shanghai Pulmonary Hospital (No. FKGG1802), Shanghai Pujiang Talent Plan (No. 2019PJD048), Shanghai Science and Technology Committee Foundation (NO. 19411950300), Shanghai Key disciplines of Respiratory (No. 2017ZZ02012), Shanghai Multidisciplinary Cooperative Project for Diagnosis and Treatment of Major Diseases, and Key Clinical Project Development Program of Shanghai.
Publisher Copyright:
© 2022 The Authors
PY - 2022/2
Y1 - 2022/2
N2 - Human epidermal growth factor receptor 2 (HER2) is a transmembrane glycoprotein receptor with intracellular tyrosine kinase activity. Its alterations, including mutation, amplification and overexpression, could result in oncogenic potential and have been detected in many cancers such as non-small-cell lung cancer (NSCLC). Such alterations are, in general, considered markers of poor prognosis. Anti-HER2 antibody-drug conjugates, e.g. trastuzumab deruxtecan (T-DXd, DS-8201) and disitamab vedotin (RC48), were recently approved for HER2-positive breast and gastric cancers. Meanwhile, several HER2-targeted drugs, such as T-DXd, neratinib, afatinib, poziotinib and pyrotinib, have been evaluated in patients with advanced NSCLC, with several of them demonstrating clinical benefit. Therefore, identifying HER2 alterations is pivotal for NSCLC patients to benefit from these targeted therapies. Recent guidelines on HER2 testing were developed for breast and gastric cancer, however, and have not been fully established for NSCLC. The expert group here reached a consensus on HER2 alteration testing in NSCLC with the focus on clinicopathologic characteristics, therapies, detection methods and diagnostic criteria for HER2-altered NSCLC patients. We hope this consensus could improve the clinical management of NSCLC patients with HER2 alterations.
AB - Human epidermal growth factor receptor 2 (HER2) is a transmembrane glycoprotein receptor with intracellular tyrosine kinase activity. Its alterations, including mutation, amplification and overexpression, could result in oncogenic potential and have been detected in many cancers such as non-small-cell lung cancer (NSCLC). Such alterations are, in general, considered markers of poor prognosis. Anti-HER2 antibody-drug conjugates, e.g. trastuzumab deruxtecan (T-DXd, DS-8201) and disitamab vedotin (RC48), were recently approved for HER2-positive breast and gastric cancers. Meanwhile, several HER2-targeted drugs, such as T-DXd, neratinib, afatinib, poziotinib and pyrotinib, have been evaluated in patients with advanced NSCLC, with several of them demonstrating clinical benefit. Therefore, identifying HER2 alterations is pivotal for NSCLC patients to benefit from these targeted therapies. Recent guidelines on HER2 testing were developed for breast and gastric cancer, however, and have not been fully established for NSCLC. The expert group here reached a consensus on HER2 alteration testing in NSCLC with the focus on clinicopathologic characteristics, therapies, detection methods and diagnostic criteria for HER2-altered NSCLC patients. We hope this consensus could improve the clinical management of NSCLC patients with HER2 alterations.
KW - amplification
KW - gene testing
KW - human epidermal growth factor receptor 2
KW - mutation
KW - non-small-cell lung cancer
KW - overexpression
UR - http://www.scopus.com/inward/record.url?scp=85124250742&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85124250742&partnerID=8YFLogxK
U2 - 10.1016/j.esmoop.2022.100395
DO - 10.1016/j.esmoop.2022.100395
M3 - Review article
C2 - 35149428
AN - SCOPUS:85124250742
VL - 7
JO - ESMO Open
JF - ESMO Open
SN - 2059-7029
IS - 1
M1 - 100395
ER -